BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36973454)

  • 1. Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome.
    Körber V; Stainczyk SA; Kurilov R; Henrich KO; Hero B; Brors B; Westermann F; Höfer T
    Nat Genet; 2023 Apr; 55(4):619-630. PubMed ID: 36973454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
    Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
    Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanistic classification of clinical phenotypes in neuroblastoma.
    Ackermann S; Cartolano M; Hero B; Welte A; Kahlert Y; Roderwieser A; Bartenhagen C; Walter E; Gecht J; Kerschke L; Volland R; Menon R; Heuckmann JM; Gartlgruber M; Hartlieb S; Henrich KO; Okonechnikov K; Altmüller J; Nürnberg P; Lefever S; de Wilde B; Sand F; Ikram F; Rosswog C; Fischer J; Theissen J; Hertwig F; Singhi AD; Simon T; Vogel W; Perner S; Krug B; Schmidt M; Rahmann S; Achter V; Lang U; Vokuhl C; Ortmann M; Büttner R; Eggert A; Speleman F; O'Sullivan RJ; Thomas RK; Berthold F; Vandesompele J; Schramm A; Westermann F; Schulte JH; Peifer M; Fischer M
    Science; 2018 Dec; 362(6419):1165-1170. PubMed ID: 30523111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
    Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
    BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of genes identified by microarray analysis in favorable neuroblastoma.
    Kamei N; Hiyama K; Yamaoka H; Kamimatsuse A; Onitake Y; Sueda T; Hiyama E
    Pediatr Surg Int; 2009 Nov; 25(11):931-7. PubMed ID: 19701758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
    Cheung NK; Zhang J; Lu C; Parker M; Bahrami A; Tickoo SK; Heguy A; Pappo AS; Federico S; Dalton J; Cheung IY; Ding L; Fulton R; Wang J; Chen X; Becksfort J; Wu J; Billups CA; Ellison D; Mardis ER; Wilson RK; Downing JR; Dyer MA;
    JAMA; 2012 Mar; 307(10):1062-71. PubMed ID: 22416102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastoma. Effect of genetic factors on prognosis and treatment.
    Brodeur GM; Azar C; Brother M; Hiemstra J; Kaufman B; Marshall H; Moley J; Nakagawara A; Saylors R; Scavarda N
    Cancer; 1992 Sep; 70(6 Suppl):1685-94. PubMed ID: 1325279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of the novel endothelin-converting enzyme genes, Nbla03145/ECEL1alpha and beta, is associated with favorable prognosis in human neuroblastomas.
    Kawamoto T; Ohira M; Hamano S; Hori T; Nakagawara A
    Int J Oncol; 2003 Apr; 22(4):815-22. PubMed ID: 12632073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous regression of neuroblastoma.
    Brodeur GM
    Cell Tissue Res; 2018 May; 372(2):277-286. PubMed ID: 29305654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth, progression and chromosome instability of Neuroblastoma: a new scenario of tumorigenesis?
    Tonini GP
    BMC Cancer; 2017 Jan; 17(1):20. PubMed ID: 28056863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
    Vandesompele J; Baudis M; De Preter K; Van Roy N; Ambros P; Bown N; Brinkschmidt C; Christiansen H; Combaret V; Lastowska M; Nicholson J; O'Meara A; Plantaz D; Stallings R; Brichard B; Van den Broecke C; De Bie S; De Paepe A; Laureys G; Speleman F
    J Clin Oncol; 2005 Apr; 23(10):2280-99. PubMed ID: 15800319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of neuronal src mRNA as a favorable marker and inverse correlation to N-myc gene amplification in human neuroblastomas.
    Matsunaga T; Shirasawa H; Tanabe M; Ohnuma N; Kawamura K; Etoh T; Takahashi H; Simizu B
    Int J Cancer; 1994 Sep; 58(6):793-8. PubMed ID: 7523310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
    Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
    Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.
    Valentijn LJ; Koster J; Zwijnenburg DA; Hasselt NE; van Sluis P; Volckmann R; van Noesel MM; George RE; Tytgat GA; Molenaar JJ; Versteeg R
    Nat Genet; 2015 Dec; 47(12):1411-4. PubMed ID: 26523776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
    Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
    PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
    Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
    Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation sequencing of microRNAs from isogenic neuroblastoma cell lines isolated before and after treatment.
    Roth SA; Knutsen E; Fiskaa T; Utnes P; Bhavsar S; Hald ØH; Løkke C; Mestdagh P; Johansen SD; Flægstad T; Einvik C
    Cancer Lett; 2016 Mar; 372(1):128-36. PubMed ID: 26708804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.